Who is sponsoring NCT00399048?

NCT00399048 is sponsored by Alza Corporation, DE, USA.

What condition does NCT00399048 study?

NCT00399048 studies Osteoarthritis, Knee, Osteoarthritis, Hip.

What drugs are being tested in NCT00399048?

Interventions: OROS hydromorphone HCL ; OxyContin.

What is the status of NCT00399048?

NCT00399048 is currently COMPLETED.

Last reviewed 2010-04-26 · How we verify

A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in Patients With Chronic Osteoarthritis

NCT00399048 Phase 3 COMPLETED

The purpose of this study was to characterize the effectiveness and safety of OROS hydromorphone HCL and OxyContin in patients with chronic osteoarthritis (OA) of the knee or hip who are receiving chronic nonsteroidal anti-inflammatory drug (NSAID) or other nonsteroidal, non-opioid analgesic (ie, acetaminophen or aspirin) therapy.

Details

Lead sponsor	Alza Corporation, DE, USA
Phase	Phase 3
Status	COMPLETED
Enrolment	140
Completion	2001-05

Conditions

Osteoarthritis, Knee
Osteoarthritis, Hip

Interventions

OROS hydromorphone HCL ; OxyContin

Primary outcomes

Two primary efficacy:The mean pain relief score at endpoint during the Maintenance Phase. The day from study medication initiation to the third day of moderate to complete pain relief on the final titrated dose during all three phases.